Germany · Delayed Price · Currency is EUR Dermapharm Holding SE Earnings Call Transcripts
Fiscal Year 2026
-
Strong H1 2026 performance driven by branded and international growth, with revenue up 5% and adjusted EBITDA up 14%. Guidance for FY 2026 is confirmed, with continued momentum expected in key segments and no material regulatory impact anticipated.
-
Q1 2026 delivered 1.1% revenue growth and a 7.5% rise in adjusted EBITDA, with margin expansion and strong free cash flow. All segments contributed, Mucos integration advanced, and the share buyback reduced free float to just above 10%.
Fiscal Year 2025
-
Revenue and adjusted EBITDA for 2025 met guidance, with margin improvements and strong cash flow. Growth is expected in 2026 from M&A, branded products, and international expansion, while restructuring and portfolio optimization continue to drive efficiency.
-
Branded pharmaceuticals drove growth in Q3 2025, with strong international and Alargo Pharma performance. Portfolio optimization and restructuring improved margins, while guidance for full-year revenue and EBITDA is expected to be met, supported by seasonal strength in Q4.